• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Sotatercept decreased vascular resistance in pulmonary arterial hypertension

byBoaz WongandHarsh Shah
April 30, 2021
in Cardiology, Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with sotatercept decreased pulmonary vascular resistance in patients with pulmonary arterial hypertension.

2. Sotatercept caused adverse side effects of thrombocytopenia and increased hemoglobin level.

Evidence Rating Level: 1 (Excellent)   

Study Rundown: Pulmonary arterial hypertension (PAH) is driven by reduced bone morphogenic protein receptor type 2 (BMP2) and increased activin signaling leading to weakened pulmonary endothelium. Sotatercept is a fusion protein that blocks activin signaling to restore the imbalance. This study evaluated the efficacy of sotatercept in patients with PAH who were receiving background therapy for the disease. The study found a significant decrease in pulmonary vascular resistance in patients treated with sotatercept compared to the control. Furthermore, patients receiving sotatercept also had improved six-minute walk distances. Thrombocytopenia and increased hemoglobin were commonly reported adverse events of sotatercept. Strengths of this study include its multicenter, double-blinded nature, and in-depth reporting on safety. However, weaknesses of the study included its small sample size and study duration, which limits the group’s ability to evaluate long-term efficacy and safety. Together, this study supports the continued investigation of sotatercept for PAH as the treatment demonstrated good safety and efficacy.

Click to read the study in NEJM

Relevant Reading: ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension

RELATED REPORTS

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule

In-Depth [randomized controlled trial]: This phase II clinical trial evaluated the safety and efficacy of a chimeric protein named sotatercept for the treatment of pulmonary arterial hypertension. Patients who had class II or III pulmonary arterial hypertension as classified by the World Health Organization (WHO) were included in the study. Patients were excluded from the study if their PAH was associated with portopulmonary disease, schistosomiasis, and human immunodeficiency virus infection. From 43 centers, 106 patients were randomized in a 3:3:4 ratio for placebo, sotatercept at 0.3mg/kg body weight, and sotatercept at 0.7 mg/kg body weight, respectively. The primary endpoint was a change in the pulmonary vascular resistance after 24 weeks. The secondary endpoint was the improvement in 6-minute walk distance after 24 weeks. The study found a decrease of 162.2 dyn·sec·cm-5 in pulmonary vascular resistance in the 0.3mg group (least-squares mean difference, -145.8 dyn·sec·cm-5; 95% confidence interval [CI],-241.0 to -50.6; P=0.003) and 255.9 dyn·sec·cm-5 in the 0.7mg group (least-squares mean difference, -239.5 dyn·sec·cm-5; 95% CI,-329.3 to -149.7; P<0.001) when compared to the placebo group. As for the 6-minute walk distance, patients in the 0.3mg and 0.7mg group improved 58.1 and 50.1 meters, respectively, compared to the 28.7 meters in the placebo group. The study found serious adverse events in 26% of patients receiving 0.7mg/kg sotatercept with thrombocytopenia and hemoglobin increase being the most common when compared to 16% in the placebo group. Overall, the study determined the safety and efficacy profile for sotatercept in the treatment of PAH for patients with background therapy for the disease.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: pulmonary arterial hypertensionsotaterceptvascular resistance
Previous Post

ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

Next Post

Tailored antiplatelet therapy improves outcomes in patients undergoing percutaneous coronary intervention

RelatedReports

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Cardiology

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

June 5, 2025
#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death
StudyGraphics

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

April 17, 2025
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Pharma

Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule

March 25, 2025
Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Cardiology

Sotatercept improves outcomes in patients with pulmonary arterial hypertension

May 2, 2023
Next Post
Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]

Tailored antiplatelet therapy improves outcomes in patients undergoing percutaneous coronary intervention

Isolated mild/moderate thrombocytopenia may not require intervention

Association of oral corticosteroid bursts with severe adverse events in children

#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up

#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Reductions in pain catastrophizing are associated with improvements in emotional functioning
  • Repeated medial branch blocks do not improve pain outcomes for thermal radiofrequency ablation
  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.